160 related articles for article (PubMed ID: 38046900)
21. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).
Koemans WJ; van der Kaaij RT; Boot H; Buffart T; Veenhof AAFA; Hartemink KJ; Grootscholten C; Snaebjornsson P; Retel VP; van Tinteren H; Vanhoutvin S; van der Noort V; Houwink A; Hahn C; Huitema ADR; Lahaye M; Los M; van den Barselaar P; Imhof O; Aalbers A; van Dam GM; van Etten B; Wijnhoven BPL; Luyer MDP; Boerma D; van Sandick JW
BMC Cancer; 2019 May; 19(1):420. PubMed ID: 31060544
[TBL] [Abstract][Full Text] [Related]
22. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
Valenzuela CD; Solsky IB; Erali RA; Forsythe SD; Mangieri CW; Mainali BB; Russell G; Perry KC; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 May; 30(5):2666-2675. PubMed ID: 36754945
[TBL] [Abstract][Full Text] [Related]
24. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
25. Malignant peritoneal mesothelioma literature review: past, present, and future.
Gregory SN; Sarvestani AL; Blakely AM
Dig Med Res; 2022 Jun; 5():. PubMed ID: 36061260
[TBL] [Abstract][Full Text] [Related]
26. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Curr Oncol; 2020 Jun; 27(3):146-154. PubMed ID: 32669924
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.
Mirnezami R; Moran BJ; Harvey K; Cecil T; Chandrakumaran K; Carr N; Mohamed F; Mirnezami AH
World J Gastroenterol; 2014 Oct; 20(38):14018-32. PubMed ID: 25320542
[TBL] [Abstract][Full Text] [Related]
28. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
Sgarbura O; Gourgou S; Tosi D; Bakrin N; Bouazza N; Delaine S; De Forges H; Pocard M; Quénet F
Pleura Peritoneum; 2019 Jun; 4(2):20190010. PubMed ID: 31417958
[TBL] [Abstract][Full Text] [Related]
29. Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer.
Canbay E; Canbay Torun B; Cosarcan K; Altunal C; Gurbuz B; Bilgic C; Sezgin C; Kaban KK; Yilmaz S; Yazici Z
J Gastrointest Oncol; 2021 Apr; 12(Suppl 1):S47-S56. PubMed ID: 33968425
[TBL] [Abstract][Full Text] [Related]
30. Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide for Intraperitoneal Mesothelioma in Severe Renal Impairment: A Case Report.
Almesned R; Azzam AZ; Aldeheshi A; Amin TM
Am J Case Rep; 2023 Mar; 24():e938192. PubMed ID: 36964641
[TBL] [Abstract][Full Text] [Related]
31. Peritoneal mesothelioma.
Greenbaum A; Alexander HR
Transl Lung Cancer Res; 2020 Feb; 9(Suppl 1):S120-S132. PubMed ID: 32206577
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Malignant Peritoneal Mesothelioma.
Levý M; Boublíková L; Büchler T; Šimša J
Klin Onkol; 2019; 32(5):333-337. PubMed ID: 31610664
[TBL] [Abstract][Full Text] [Related]
33. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
[TBL] [Abstract][Full Text] [Related]
34. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
35. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.
Alexander HR; Bartlett DL; Pingpank JF; Libutti SK; Royal R; Hughes MS; Holtzman M; Hanna N; Turner K; Beresneva T; Zhu Y
Surgery; 2013 Jun; 153(6):779-86. PubMed ID: 23489943
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
[TBL] [Abstract][Full Text] [Related]
37. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
38. Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience.
Deraco M; Sinukumar S; Salcedo-Hernández RA; Rajendra VJ; Baratti D; Guaglio M; Nizri E; Kusamura S
Eur J Surg Oncol; 2019 Nov; 45(11):2103-2108. PubMed ID: 31230982
[TBL] [Abstract][Full Text] [Related]
39. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
[TBL] [Abstract][Full Text] [Related]
40. Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases.
Gros L; Szturz P; Diciolla A; Kirchner V; Peters S; Schaefer N; Hubner M; Digklia A
Front Oncol; 2021; 11():704295. PubMed ID: 34222029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
